GlassScriptPhysician profile
Qinglong Hu
NPI 1295839405
$6,484.07
in general payments reported to CMS, 2019-2025
8 companies · $80.74 in 2025
The $80.74 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $6,013 · 2022: $117 · 2023: $125 · 2025: $80.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ventana Medical Systems, INC. | $6,000.00 | 2021 | |
| Blueprint Medicines Corporation | $125.00 | 2023 | |
| Amgen INC. | $118.71 | 2019 | |
| Myriad Genetic Laboratories, INC. | $116.67 | 2022 | |
| Janssen Biotech, INC. | $80.74 | 2025 | Rybrevant |
| Dova Pharmaceuticals | $15.35 | 2019 | |
| Siemens Medical Solutions USA, INC. | $14.82 | 2019 | |
| Myovant Sciences INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qinglong Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.